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The incidence of cutaneous melanoma is on the rise. While a significant amount 
of work has been done to evaluate the importance of various demographic, pathologic 
and clinical information in patients with melanoma in situ and stage I melanoma, no 
study to our knowledge has comprehensively evaluated this information. In this paper, 
we performed a retrospective case review of the outpatient management of 208 lesions of 
melanoma in situ and stage I melanoma during the years of 1988-2005. This included 
137 melanoma in situ lesions and 71 stage I melanoma lesions. We sought to evaluate 
this continuum of early melanoma because we deemed these to be the vast majority of 
melanoma lesions presenting to dermatologic surgery centers while realizing that these 
two categories present two unique entities. 53.85% of the lesions were present in male 
patients while 46.15% of the lesions were diagnosed in female patients. The mean age of 
the entire patient population is 65.57 years. The mean age of patients that presented with 
malignant melanoma, superficial spreading is 63.94 years, while the mean age of the 
patient population with melanoma in situ is 66.67 years. The mean age of males is 68.34 
years. The mean age of females is 65.5 1 years. Of the lesions in males, 37.50% are 
malignant melanoma while the remaining 62.50%> are melanoma in situ. Of the lesions 
on females, 30.21% are malignant melanoma while 69.79% were diagnosed as melanoma 
in situ. Overall, the mean lesion size was 13.90 mm in diameter. The mean size of all of 
the melanoma in situ lesions is 14.50 mm, while the mean size of all lesions diagnosed as 
malignant melanoma is 1 1.68 mm. The mean depth of the malignant melanoma lesions is 
0.42 mm. 
From our data, stage I melanoma, melanoma in situ, and all lesions considered in 
aggregate show a statistically significant predilection to the head and neck areas. 
Additionally, when comparing stage I melanoma to melanoma in situ, the former lesions 
show a significant propensity for the trunk. Additionally, melanoma in situ lesions of the 
trunk showed a significant propensity for the right side. Our data demonstrates a low 
local recurrence rate of 4.38% for melanoma in situ lesions and a 1.41%’ local recurrence 
rate for stage 1 lesions. Our data indicates that all of the local recurrence occurred on the 
head and neck. Analysis suggests that lesions of the head and neck are more likely to 
recur than lesions elsewhere on the body. Further analysis did not suggest a difference of 
local recurrence rates between those patients treated with currently recommended clinical 
surgical margins of 5 mm in melanoma in site and l cm in stage I melanoma. All 
recurrences in our study occurred in patients treated with the recommended surgical 
margins. Finally, lesions of the head and neck were more likely to be melanoma in situ 
lesions than stage I melanoma in a statistically significant fashion. 
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The incidence of melanoma of the skin has rapidly risen (1). An estimated 59,580 
new cases of invasive melanoma of the skin will occur in 2005 resulting in approximately 
7,700 deaths. Additionally, another 46,170 new cases of melanoma in situ are expected 
in 2005 (1). At times progressive and deadly, melanoma is a disease of both the young 
and old. Melanoma is one of the most serious cancers when measured by years of life 
lost (2). Fortunately today, due to early detection and aggressive treatment, the majority 
of patients presents with localized disease that is limited to the skin (3) which decreases 
the mortality rate from melanoma. Increased awareness due to preventive skin cancer 
education programs has led to the presentation of melanoma at younger ages and earlier 
stages of disease (4, 5). 
In the current staging system for melanoma, the American Joint Committee on 
Cancer (AJCC) classifies lesions based on tumor thickness (6). This staging system is 
classified by thresholds that correlate with clinical management and prognosis of 
melanoma patients. The AJCC designates stage I as tumors less than 1.0 mm thickness, 
stage II between 1.01-2.0 mm thickness, stage III between 2.01-4.0 mm thickness, and 
stage IV greater than 4.0 mm thickness. According to an AJCC study, tumor thickness 
was the most powerful independent prognostic factor for patients with primary cutaneous 
melanoma (6). Early melanoma includes melanoma in situ and invasive lesions less than 
1.0 mm in depth (7). 
Detection and treatment of melanoma at its earliest stages is usually curative. 
Detection of melanoma at later stages often leads to significant morbidity and mortality 
(8). Local surgical treatment of early melanoma remains the standard of care, but the 

technique used, especially in relation to the clinical surgical margins remains an area of 
ongoing debate in current literature. The earliest reports by Samson Handley in 1905 
suggested the need for the removal of 2 inches of subcutaneous tissue down to the fascia 
for melanoma (9). In 1962, Petersen, et al. suggested the need for up to 5 cm margins of 
normal skin even for thin invasive melanoma (10). These aggressive approaches were 
based on their belief that these treatments were necessary to prevent local recurrences and 
metastatic disease. Currently, most physicians follow the National Institutes of Health 
recommendation of 5 mm of clear clinical margins for melanoma in situ and 10 mm of 
clear clinical margins for stage I melanoma (7). In the case of melanoma in situ, local 
excision results in a 99% disease-free, long-term survival with local recurrence 
accounting for the other 1%. In the case of thin invasive melanoma, surgical removal 
results in greater than 90% disease-free, long-term survival (7). 
Obtaining standard surgical margins in the treatment of early melanoma is not 
always practical. Often patients of advanced age or patients with lesions in cosmetically 
difficult areas require the use of narrower clinical margins or alternative therapies. 
Imiquimod, cryotherapy, and Q-switched ruby laser have all been suggested as 
alternatives to surgical treatment especially in patients of advanced age with melanoma in 
situ. Additionally, the use of clinical margins less than those previously suggested as the 
standard of care, especially in cosmetically sensitive areas such as the face, have been 
used with varying success (1 1-13). Although most physicians agree that obtaining 5 mm 
and 10 mm clinical margins for melanoma in situ and thin invasive melanoma 
respectively is optimal, significant exploration around the use of smaller margins 
continues. Although a number of researchers have evaluated the use of narrow margins 
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for intermediate invasive melanoma (13-15), few have examined the use of narrow 
margins in melanoma in situ and early invasive melanoma (12). Further research is 
needed to evaluate the use of narrow margins because the current evidence is not 
sufficient to address optimal surgical margins especially in the case of early melanoma. 
The importance of cure at the time of initial treatment is due to the fact that local 
recurrence of melanoma may lead to considerably worse prognosis (16. 17). Some 
studies have suggested an association between narrow excision margins and recurrence 
rates (17). Reports of the rate of local recurrence of all melanomas even melanoma in 
situ vary dramatically from 0-50% within 5 years (18-20). One recent article reported a 
6.8% 5-year recurrence rate for surgically removed melanoma in situ lesions. Further, 
this study suggested that treatment other than excision as well as site of involvement were 
significant prognostic variables in relation to recurrence. Patient age at treatment was not 
found to be a significant variable in this study (20). 
In addition to the dehate regarding surgical margins in melanoma, the optimal 
excision technique employed for the removal of early melanoma remains controversial. 
Some physicians suggest the use of Mohs’ micrographic surgery (21, 22). though the use 
of frozen sections for evaluation of disease-free margins remains controversial. Staged 
excision procedures using permanent sections are often employed for the treatment of 
melanoma (23). This technique employs serial sections when necessary to spare tissue 
while ensuring the removal of the entire lesion. 
Because of the lack of definitive guidelines regarding the optimal management of 
early stage melanoma, we reviewed a range of established clinical parameters to clarify 
better the useful treatment approaches for early melanoma. Our review that follows 
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presents one of the most complete and thorough reviews of treatment and pathological 
criteria of melanoma in situ and stage 1 melanoma. 

Specific Aims and Hypotheses 
Aims 
1) To define practical clinical parameters for the treatment of early melanoma including 
clinical margins. 
2) To evaluate predictors of recurrence of early melanoma. 
Hypotheses: 
1) Age, sex, body site, and treatment modalities used in the treatment of melanoma 
affect the recurrence rate. 
2) However, “suboptimal” margins do not affect recurrence rates; therefore current 
recommendations of 5 millimeters for melanoma in situ and 10 millimeters for stage 
melanoma need not he absolute guidelines under certain circumstances especially in 
cosmetically sensitive areas and in patients with advance age. 

Methods 
We performed a retrospective case review of the outpatient management of 
melanoma in situ and stage I melanoma at Yale Dermatologic Surgery and Cutaneous 
Oncology Section in the Department of Dermatology. The study period was 1988-2005. 
The study was approved under Human Investigation Committee protocol # 27327. In 
order to define our patient population, we performed a search of all pathological 
specimens for any diagnosis including melanoma. All patients with the diagnosis of 
melanoma in situ and stage I melanoma, superficial spreading type with a depth less than 
1.0 mm were included in the study. In patients with multiple primary lesions, each lesion 
was treated as a separate individual case. 
Patients who presented with stage I melanoma, superficial spreading type with a 
depth greater than 1.0 mm were excluded. Likewise, patients with stage I melanoma, 
acral lentiginous type and nodular type were excluded because they represent unique 
diagnostic and treatment entities. Also excluded from statistical analysis were all patients 
treated with non-surgical methods including imiquimod and Q-switched Ruby Laser. 
These excluded patients are discussed anecdotally in the results and discussion sections. 
Patients that were definitively treated by other providers who were referred as local 
recurrences were likewise excluded. Additionally, patients with metastatic disease at 
presentation were excluded. Patients who were not definitively treated at our clinic 
including those who presented for consultation only or those patients who were referred 
to other physicians for definitive treatment and often sentinel node biopsy were likewise 
excluded. Although rare, patients with incomplete or unavailable charts were excluded. 
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All data was recorded in a Microsoft Excel 2002 spreadsheet under human 
investigation committee protocol and all data was analyzed using the chi-square test in 
SAS program (SAS Institute Inc. SAS Release 8.2. Cary, NC; 2001) unless otherwise 
indicated. Margin data was recorded from the operative report and added to the margins 
of the previous stage(s) of excision if multiple stages were taken. In the rare case in 
which data about the clinical surgical margins or clinical size of lesion was not recorded 
in the patient chart, these values were calculated using the measurements of the 
pathological specimen with the assumption that specimens shrink approximately 30 
percent from their in vivo state. In the case when clinical margins were not recorded, the 
width of the ellipse or the diameter of the circle of the pathological specimen was 
multiplied by 1.3 and the larger diameter of the lesion was subtracted to approximate thee 
clinical margin. Conversely, if the clinical size of the lesion was not recorded, then the 
width of the ellipse or the diameter of the circle of the pathological specimen was 
multiplied by 1.3 and then the recorded clinical margin was subtracted from the 




Inclusion & Exclusion 
A total of 275 patients were identified using the study criteria. A total of 77 
patients were excluded (see Table 1). The charts of 14 patients were either incomplete or 
unavailable. 3 patients with malignant melanoma, acral lentiginous type and 2 with 
nodular type were excluded. A total of 14 patients were treated with non-surgical 
modalities including 10 treated with imiquimod and 4 treated with Q-switched ruby laser. 
Of note, 7 of the 10 patients that were treated with imiquimod have been followed 
clinically without any indication of recurrent melanoma in situ. Three patients presented 
with local recurrences. Two patients treated with the laser therapy required further 
excision while the other 2 required no further treatment. 
Melanoma in situ lesions on three patients proved extremely difficult to remove 
completely; alter multiple stages with positive margins, the decision was made to follow 
these lesions clinically. Other excluded patients include: 21 patients who were referred 
to other physicians for definitive treatment and sentinel node biopsy; 2 patients that 
presented for consultation only; 4 patients who presented with local recurrence; and 4 
patients who presented with metastatic disease. Finally, 10 patients with stage I 
melanoma, superficial spreading type were excluded with lesions between 1.0 mm and 
2.9 mm in depth. Of note, our charts including outside consultation notes on these 




A total of 198 patients with 208 primary lesions were evaluated in the statistical 
analysis that follows (2 patients were treated for 2 primary lesions and 2 patients were 
treated for 3 primary lesions). 
Patient Demographics 
112 (53.85%) of the lesions were present on male patients while 96 (46.15%) of 
the lesions were present on female patients. The mean age of the entire patient 
population was 65.57 +/- 14.43 years. The mean age of patients that presented with stage 
I melanoma, superficial spreading was 63.94 +/- 16.76 years, while the mean age of the 
patient population with melanoma in situ is 66.67 +/- 12.78 years. The mean age of 
males was 68.34 +/- 13.08 years. The mean age of females was 65.5 1 +/- 15.00 years. 
The mean time since treatment was 6.78 +/- 4.17 years in the entire patient population 
with a median of 6.67 years. The range was 2.5 months to 14 years. 
Description of Lesions Rased on Diagnosis 
In the entire patient population, 71 (34.13%) of the lesions were stage I melanoma 
while the remaining 137 (65.87%) were melanoma in situ. Of the lesions on males, 42 
(37.50%) were stage I melanoma while the remaining 70 (62.50%) are melanoma in situ. 
Of the lesions on females, 29 (30.21%) were stage I melanoma while 67 (69.79%) were 
diagnosed as melanoma in situ. 
Description of Lesions Rased on Size and Depth 
In order to evaluate the size of the lesion, the greatest clinical measurement was 
used. Overall, the mean lesion size was 13.90 +/- 8.62 mm in diameter. The mean size 
of all of the melanoma in situ lesions was 14.50 +/- 8.84 mm, while the mean size of all 
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lesions diagnosed as stage I melanoma was 1 1.68 +/- 7.02 mm. The mean depth of the 
stage I melanoma lesions was 0.42 +/- 0.21 mm. 
Description of Lesions Rased on Location 
Table 2 illustrates the distribution of stage I melanoma and melanoma in situ by 
body site and side. Body site is divided into 4 categories: head and neck (HN). upper 
extremity (UE), trunk (T), and lower extremity (LE). Laterality is divided into left, 
middle, and right. In Table 3 the lesions are further divided by diagnosis, body site 
category, and side. Finally, in Table 4 the lesions of the trunk and head and neck are 
separately divided into specific sites within the specific body site category. For the trunk 
lesions, they are divided into front, back, and other (including shoulder and flank). For 
the head and neck lesions, 10 separate subsets were employed: cheek, chin, ear, eyelid, 
forehead, lip, neck, nose, scalp, and temple. 
Pathologic Descriptors of Stage I Melanoma 
Table 5 allocates the stage I melanoma lesions into categories based on 
pathological criteria. These criteria include: the Clark's level, the presence or absence of 
ulcerations, and the growth phase. 
Recurrences 
The overall local recurrence rate observed in our study population was 3.37% 
with a 4.38% local recurrence rate for melanoma in situ lesion and a 1.41 % local 
recurrence rate for stage 1 melanoma. We are not aware of any metastatic disease 
occurring in our patient population. In our entire study population including melanoma 
in situ and stage I melanoma, there was an overall 4.17% recurrence rate among female 

patients and a 2.68% recurrence rate among male patients. Similarly, 4.27% of the 
lesions on patients older than the mean age recurred while only 2.68% of the lesions on 
patients younger than the mean recurred. All local recurrences arose on the head and 
neck. The overall recurrence rate on the head and neck was 5.88% (6.81% for melanoma 
in situ, 3.22% for stage I melanoma). Finally, 4.65% of lesions larger than the mean size 
when measured hy greatest clinical diameter recurred while only 2.46% of lesions 
smaller than the mean size recurred locally. All of this data along with corresponding 
statistical values are reported in Table 6. The corresponding values from statistical 
analysis of potential predictors of recurrence are included in this table. 
Recurrences based on Margins 
Margins of 2-10 mm were required to remove the melanoma in situ lesions with a 
mean of 5.15 mm and a standard deviation of 1.60 mm. Margins of 3-20 mm were 
employed to eradicate the stage 1 melanoma lesions with a mean of 9.11 mm and a 
standard deviation of 3.00 mm. A vast majority of both sets of lesions were removed 
successfully using the recommended 5 mm for melanoma in situ and 1 cm for stage I 
melanoma. Under certain circumstances, narrower margins were employed, while in 
other cases, larger clinical margins were necessary after repeated stages to remove the 
entire lesion. The exact margins and number of cases that employ each respective margin 
are reported in Table 7. 
Recurrences based on Stages and Margins 
Table 8 shows recurrences based on the number of stages necessary to remove the 
lesion. For most lesions, only one stage was required to eradicate all disease although up 

to five stages were required for one case of melanoma in situ. All local recurrences of 
melanoma in situ and stage I melanoma occurred in excisions with a single stage. 
Non-Surgical Treatment of Melanoma In Situ 
As noted previously, 10 lesions were treated with imiquimod while 4 patients 
were treated with Q-switched Ruby laser. Seven of the 10 patients treated with 
imiquimod showed pathological clearance. During our study period, 3 of the 10 or 30% 
of patients presented with local recurrences. Of the 4 patients treated with Q-switched 
Ruby laser, 2 cleared clinically while 2 required further excision. 
Diagnosis Data 
In order to evaluate the impact of sex, age, body site, and lesion size on the 
diagnosis of melanoma in situ or stage I melanoma, the number of stage I melanoma 
patients in relation to each of these parameters was recorded as seen in Table 9. 30.21% 
of female patients versus 37.50% of male patients in our patient population were 
diagnosed with stage I melanoma. 38.10% of patients older than the mean age of our 
population were diagnosed with stage I melanoma versus 31.45% in patients younger 
than the mean population. Only 26.05% of the lesions of the head and neck were stage I 
melanoma versus 44.94% of the lesions diagnosed on the remainder of the body. When 
lesion size was considered, 37.70% of the lesions larger than the mean size were stage I 
melanoma while 57.38% of lesions smaller than the mean size were stage I melanoma. 
Evaluating Trends 
Using data from Table 10, we evaluated potential trends in the depth and size of 
lesions as well as patient age and sex over three consecutive five year periods. In order to 
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increase the number of lesions for evaluation and statistical power of the analysis, our 
entire spectrum of early melanoma including melanoma in situ lesions as well as stage 1 
were combined. Corresponding statistical values are included for each analysis performed 




Based on the recent literature as noted in our introduction, this work presents one 
of the most complete and comprehensive case reviews of patients with melanoma in situ 
and stage I melanoma. Most previous work focuses on just one of the many clinical 
parameters that we evaluated in our study. The authors realize that one major 
shortcoming of some of our analysis is that the cases of melanoma in situ were combined 
with stage I melanoma cases. Previous studies and reviews have evaluated these two 
entities as early melanoma (24). Although these two entities have very different 
biologies, especially in regards to the metastatic potential of stage I melanoma (25), local 
surgical treatment with narrow margins remains the widely accepted standard of care for 
both processes. Furthermore, these entities represent a majority of melanoma treated by 
dermatologic surgeons. In order to account for the differences between melanoma in situ 
and stage I melanoma, when possible, analysis was done on the two groups separately 
and aggregately. 
The average time since treatment records only a gross estimate of disease-free 
survival in these patients. When noted in chart, date of death was taken into account 
when calculating time since treatment. Patients have not yet been contacted for follow¬ 
up, and most likely we are unaware of some patients who are now deceased. We also are 
aware that some patients may have been treated at other institutions, though none of the 
patients analyzed in this section submitted a request for transfer of their medical records. 





The larger proportion of male patients (53.85% versus 46.15%) did not indicate a 
statistically significant difference in gender distribution (p-value=0.2734). However, our 
patient population with a mean age of almost 66 years did prove it) be a relatively older 
population compared with recently reported data, including one that reported an average 
age of 46 years for patients with these lesions (which included melanoma in situ and 
stage I lesions) (4). One interpretation of this data could suggest that there exists a poor 
awareness among the patient population treated in our study about the signs of 
melanoma. This data hints at the need for further educational programs about melanoma. 
The difference in age between patients with melanoma in situ and stage I melanoma did 
not reach statistical significance. 
Lesion Characteristics 
From our data, stage I melanoma, melanoma in situ, and all lesions considered in 
aggregate show a statistically significant (pcO.OOl) predilection to the head and neck 
areas, potentially reflecting a referral bias based on expertise. Additionally, when 
comparing stage 1 melanoma to melanoma in situ, the former lesions show a propensity 
for the trunk (26.76% versus 14.60%). Additionally, the 19 melanoma in situ lesions of 
the trunk showed a propensity for the right side (55% on the right versus 20% on the left). 
No other significant relationships were observed within the specific side or site of the 
body. 
The distribution of melanoma in situ lesions in regard to head and neck, trunk, 
upper extremity, and lower extremity were fairly consistent with recently published data 
(20). Our results suggest a slightly higher preponderance of lesions on the head and neck 
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areas (64.23% versus 53.4%) with a smaller percentage of trunk (14.60% versus 20.3%) 
and lower extremity (10.95% versus 16.4%) lesions when compared to the previously 
mentioned study. These differences did not prove statistically significant. 
Unfortunately, due to the significant number of pathological reports that omitted 
ulceration and growth phase information, little information can be gleaned from this data 
about the stage I melanoma lesions in our study. None of the pathological data indicated 
the presence of ulcerations within these lesions. Based on discussions with our 
dermatopathologists, we can likely assume that none of these lesions were ulcerated. 
This is not an unexpected result as ulceration is often seen in later stages of melanoma 
and would warrant further evaluation. Growth phase remains a difficult pathological 
criterion to evaluate with recent literature suggesting some inter-observer disagreement 
among non-specialist pathologists (26). Interestingly, only two stage I melanoma lesions 
in our study were Clark’s level I. A vast majority of the lesions were Clark’s level II. 
Overall Recurrence Data 
Based on recent published data, our data suggests an extremely low recurrence 
rate overall and also when divided between melanoma in situ and stage I melanoma. 
Zalaudek, et al. report a 5-year local recurrence rate of 6.8 +/- 1.3% for melanoma in situ 
lesions (20). Our data shows a local recurrence rate of 4.38% for melanoma in situ 
lesions. Additionally, Ng, et al. reported a 2.58% local recurrence rate for stage I 
melanoma. Again, our data demonstrate a 1.41% local recurrence rate for similar lesions. 
Our data indicate that all of the local recurrence occurred on the head and neck. 
These data prove to be extremely interesting when compared to previous studies. In one 
study of stage I melanoma lesions by Ng, et al. (16), the distribution of sites in which 
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recurrences occurred were much more evenly distributed among the head and neck, 
trunk, and extremities. In their study, only 26% of the local recurrences occurred on the 
head and neck. The significance of the difference in their experience as well as the 
ability to extrapolate those data to our experience with melanoma in situ is an area that 
requires further analysis. 
Predictors of Recurrence 
Using data from Table 6, we evaluated the significance of sex, age, body site, 
lesion size, and specific diagnosis on recurrence rates. The only factor that proved to be a 
statistically significant predictor of recurrence for the lesions in aggregate and also when 
evaluated separately by melanoma in situ and stage I melanoma was the location of the 
lesion. In aggregate, our analysis suggested that lesions of the head and neck are more 
likely to recur (p=0.0186) than lesions elsewhere on the body. This finding is in 
agreement with another recent report that also showed that melanoma originating on the 
head and neck was a statistically significant predictor of recurrence (20). This implies 
the need for caution when removing lesions of the head and neck and interpreting the 
pathological specimens. Lesions in patients older than the mean age were 2.5 time more 
likely to recur than those in patients younger than the mean age, but this did not prove to 
be statistically significant. In a larger cohort of patients, this may prove to be a more 
significant predictor of recurrence, although previous reports have shown results similar 
to ours (20). 
The sex of the patient and the size of the lesions likewise did not show statistical 
significance, though based on the odds ratio our data suggests that lesions on female 
patients are 1.5 times more likely recur and lesions larger than the mean size are 1.2 times 
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more likely to recur. The applicability of this information for all patients with melanoma 
in situ or stage I melanoma requires further analysis and future studies in a larger cohort 
of patients. The pathological diagnosis of melanoma in situ did not prove to be a 
statistically significant predictor of recurrence. This may reflect a more aggressive 
surgical treatment of stage I melanoma as compared to melanoma in situ. In our analysis, 
we did not evaluate the impact of the depth of invasion of the stage one lesions on 
recurrence because only one of the 71 lesions recurred and thus proper statistical analysis 
was not possible for this parameter. 
Important Treatment considerations 
Treatment for each unique case must be tailored to the patient based on the 
information the clinician obtains about the lesion. Each instance in which margins less 
than generally accepted standards of 5 mm for melanoma in situ and 1 cm for stage I 
melanoma was tailored to the specific case. In a number of instances in patients, 
especially of advanced age with stage I melanoma, an initial diagnosis of melanoma in 
situ was made by biopsy and thus margins less than I cm were indicated for the initial 
excision. If pathologic sections of these lesions revealed disease-free margins, close 
clinical follow-up was at times deemed the best option for the patient. This was the case 
in which a 3 mm margin was used on one patient who. after definitive treatment, was 
diagnosed with stage I melanoma. Patients were made aware of the significance of the 
diagnosis and importance of close monitoring of the site of involvement. In a number of 
these patients, alter being given the option of another stage of excision or monitoring, the 
patient chose to monitor closely. Again in these cases, patients were educated about the 
risks and benefits of monitoring. The ability to closely monitor the aforementioned 
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patients pivots on a clear and strict understanding of disease-free clinical margins 
between the surgeon and pathologist. 
That being stated, our data suggests that clinical surgical margins narrower than 
standard recommended margins of 5 mm clinical margins for melanoma in situ and 1 cm 
clinical margins for stage I melanoma may prove to be acceptable on a larger scale. Each 
case in our panel of patients in which margins narrower than standard recommended 
margins were employed was carefully evaluated. 
“ Suboptimally Treated’' Patients: The Impact of Surgical Margins Employed 
Differing from other studies (14, 16), our analysis did not suggest a significant 
difference of local recurrence rates between those patients treated with currently 
recommended clinical surgical margins of 5 mm in melanoma in situ and 1 cm in stage I 
melanoma. As discussed previously, various factors led to many cases in which smaller 
surgical margins were used. In our patient population, none of the local recurrences 
occurred in a patient that was treated with narrower margins than recommended. The six 
melanoma in situ lesions that recurred were all treated with 5 mm surgical margins, while 
the one stage one melanoma lesion that recurred locally was treated with a 1 cm margin. 
Thus, our experience again suggests that under the right circumstances and in specific 
situations, narrower surgical margins can be successfully employed for melanoma in situ 
and stage I melanoma without compromising disease eradication. Thus, current 
recommendations for clinical surgical margins may not need to be strict guidelines. The 
current guidelines for margins should remain the goal in each case until further controlled 
studies are carried out to evaluate narrow margins. Again, further study is warranted. 
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Impact of Number of Stage Employed 
As was previously mentioned, all 7 local recurrences occurred in patients who had 
been treated with a single stage excision. The clinical significance of this finding is yet 
to be determined. To date, we are unaware of other studies that have evaluated the 
impact of the number of stages of excision on recurrence. In reviewing the pathology 
reports from these recurrences, a number of the reports suggest the presence of tumor 
“close to but not on the specimen margin” or some similar statement. In one report, the 
tumor was noted to be “greater than 1 mm from the surgical margin.” Although outside 
the scope of the study, further investigation into exactly how the specific pathologists use 
the term “close” under these circumstances may prove to he useful for future studies. 
Predictors of Invasions 
From our cohort of patients, we were interested in any clinical or demographic 
information that may predict the presence of invasion. From our study, women are no 
more likely to have invasive disease. Men and women are equally likely to suffer from 
stage I melanoma. Similarly, advanced age as defined by patients older than our mean 
population age are not more likely to have stage I melanoma than melanoma in situ. 
Therefore, more aggressive lesions such as stage I melanoma in our study are equally 
likely to present in younger patients (again defined as patients younger than the average 
patient population) and older patients. Likewise, larger lesions were not more likely to be 
stage I melanoma than melanoma in situ. 
On the other hand, lesions of the head and neck were more likely to be melanoma 
in situ lesions than stage I melanoma in a statistically significant fashion (p=0.0033). 
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This statistical significance may reflect the impact of sun exposure on the incidence of 
early melanoma on the head and neck areas. 
Analysis of Trends 
To evaluate trends in the diagnosis of these lesions, the number of lesions with a 
depth greater than or less than the mean depth at diagnosis of stage I melanoma was first 
evaluated over three separate, approximately five year periods. One may hypothesize 
that lesions are currently diagnosed at early stages due to better patient and physician 
awareness and thus the lesions should show a trend of decreasing depth over these time 
periods. Unfortunately, no statistically significant decrease in the depth of lesions was 
seen. Conversely, evaluation of these stage I lesions indicated no statistically significant 
increase in the depth at diagnosis. 
Collectively, these lesions were then evaluated based on trends in diagnosis by 
patient sex, the number of patients older than or younger than the mean patient age, and 
the number of lesions greater then or less than the mean lesion size. Although combining 
stage I melanoma lesions with melanoma in situ lesions may not prove completely 
accurate, the idea is to evaluate any potential trends in the diagnosis of the continuum of 
early melanoma. Neither patient sex nor lesion size showed any statistically significant 
trends. The number of patients older than the mean patient age. however, indicated a 
statistically significant (p=0.0271) increase over the three time periods. One of the major 
confounding factors in this evaluation is significant increase in the age of the population, 
and thus no clear determination about the trend of increasing age in our patient 




Despite a large body of literature about practical consideration in the treatment of 
melanoma in situ and stage I melanoma, significant gaps in the understanding of practical 
considerations exists. Our study provides a comprehensive analysis of 208 cases and 
evaluates the significance of various demographic, pathological and clinical data for these 
cases. Findings from our study suggests a need for more studies into the significance of 
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Figure 1: Calculation of Omitted Data: Representation of our method for calculating missing 
lesion size and clinical surgical margin data. To calculate omitted clinical surgical margins length “b” was 
subtracted from “a” and divided by 2. To calculated omitted lesion size, the clinical surgical margin was 
multiplied by 2 and subtracted from value “b.” 
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Tables 
Patients Excluded and Exclusion Criteria 
Malignant Melanoma, Type # 
Nodular 2 
Acral Lentiginous 3 
Malignant Melanoma, Superficial Spreading, Depth 
1.0 mm - 2,9 mm 10* 
Non-Surgical Treatment 
Imiquimod 10** 
Q-switched ruby laser 4 
Other 
Patients never cleared of disease pathologically 
who were followed clinically 3 
Patient referred for definitive treatment 21 
Consultation only 2 
Local recurrence at presentation 4 
Metastatic disease at presentation 4 
Charts unavailable or incomplete 14 
Table 1: Patients Excluded and Exclusion Criteria: The number of patients and reasons for 
exclusion from our study population. *of die 10 patients with thickness >1.0 mm. no recurrences occurred. 










HN 31 43.66% 88 64.23% 119 57.21% 
UE 8 11.27% 15 10.95% 23 11.06% 
T 19 26.76% 20 14.60% 39 18.75% 
LE 13 18.31% 14 10.22% 27 12.98% 
total 71 100.00% 137 100.00% 208 100.00% 
Table 2: Lesion Site by Category: Lesions divided into categories based on diagnosis (melanoma 
in situ or stage I melanoma) raid body site. Abbreviations: MM. malignant melanoma (specifically stage I 
melanoma in our evaluation); MIS, melanoma in situ; HN. head and neck; UE. upper extremity; T. trunk; 










Left 28 39.44% 62 45.26% 90 43.27% 
Middle 10 14.08% 18 13.14% 28 13.46% 
Right 33 46.48% 57 41.61% 90 43.27% 
total 71 100.00% 137 100.00% 208 100.00% 
Stage 1 Melanoma 
LEFT 
% of 
site MIDDLE % RIGHT % total 
HN 13 41.94% 4 12.90% 14 45.16% 31 
UE 4 50.00% 0 0.00% 4 50.00% 8 
1 5 26.32% 6 31.58% 8 42.11% 19 
LE 6 46.15% 0 0.00% 7 53.85% 13 
total 28 10 33 71 
Melanoma in situ 
LEFT % MIDDLE % RIGHT % 
HN 43 48.86% 13 14.77% 32 36.36% 88 
UE 8 53.33% 0 0.00% 7 46.67% 15 
T 4 20.00% 5 25.00% 11 55.00% 20 
LE 7 50.00% 0 0.00% 7 50.00% 14 
total 62 18 57 137 
Table 3: Lesion Site by Side and Category: Lesions divided by diagnosis, body site, and 
laterality. Abbreviations: MM, malignant melanoma (specifically stage I melanoma in our evaluation); 




MIS % of MIS MM % of MM 
Back 12 60.00% 10 52.63% 
Front 5 25.00% 3 15.79% 
Other 3 15.00% 6 31.58% 
total 20 19 
Head/Neck 
MIS % of MIS MM % of MM 
CHEEK 27 30.68% 1 1 35.48% 
CHIN 4 4.55% 1 3.23% 
EAR 3 3.41% 5 16.13% 
EYELID 2 2.27% 2 6.45% 
FOREHEAD 10 11.36% 3 9.68% 
LIP 4 4.55% 1 3.23% 
NECK 4 4.55% 1 3.23% 
NOSE 26 29.55% 4 12,90% 
SCALP 4 4.55% 2 6.45% 
TEMPLE 4 4.55% 1 3.23% 
total 88 31 
Table 4: Site Subsets for Trunk and Head/Neck: Lesions divided by diagnosis and specific 
sites of the trunk and head and neck areas. Abbreviations: MM, malignant melanoma (specifically stage I 
melanoma in our evaluation); MIS, melanoma in situ. 
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Table 5: Pathological Descriptors of Stage I Melanoma: Stage I melanoma lesions divided 
by Clark's level, presence or absence of ulceration, and growth phase. Abbreviations: Y. presence of 












Melanoma In situ 6 137 4.38% 
Stage 1 Melanoma 1 71 1.41% 
Overall Recurrence 7 208 3.37% 
Sex by Recurrence 
Female 4 96 44 7% 
Male 3 112 2.68% 
total 7 208 3.37% 1.5808 0.2505 
Age by Recurrence 
age > mean age 5 117 4.27% 
age < mean age 2 91 2.20% 
Total 7 208 0.2441 2.5962 
Body Site by Recurrence 
Head/Neck 7 119 5.88% 
Other 0 89 0.00% 
Total 208 0.0186 N/A 
Lesion Size by Recurrence 
Lesion > mean size 4 86 4.65% 
Lesion < mean size 3 122 2.46% 
total 208 1.2477 0.7751 
Diagnosis by Recurrence 
Melanoma in situ 6 137 4.38% 
Stage I melanoma 1 71 1.41% 
total 208 0.1982 0.2695 
Table 6: Recurrence Data: Recurrence data based on diagnosis, sex, age, body site, and lesion size. 
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2 3 0 
3 12 0 
4 3 0 
5 107 6 
7 1 0 
10 1 1 0 
total 137 6 






3 1 0 
5 16 0 
7 1 0 
8 1 0 
10 47 1 
12 2 0 
15 1 0 
20 2 0 
total 71 1 
Table 7: Clinical Margins: Clinical surgical margins, number of patients in which each margin was 
employed, and the number of recurrences based on margins. Abbreviations: mm, millimeters. 
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1 Stage Excision 112 6 54 1 7 
2 Stage Excision 19 0 14 0 0 
3 Stage Excision 3 0 3 0 0 
4 or greater Stage Excision 3 0 0 0 0 
total 137 6 71 1 7 














Sex by Diagnosis 
Female 29 96 30.21% 
Male 42 112 37.50% 
total 208 0.285 0.74 
Age by Diagnosis 
Age > mean age 32 84 38.10% 
Age < mean age 39 124 31.45% 
total 208 0.0571 0.5856 
Body Site by Diagnosis 
HN 31 119 26.05% 
Other 40 89 44.94% 
total 208 0.0033 0.4358 
Lesion Size by Diagnosis 
Lesion > mean size 46 122 37.70% 
Lesion < mean size 35 61 57.38% 
total 81 183 0.9253 0.1073 
Table 9: Diagnosis Data: Diagnosis of stage I melanoma based on sex, age, body site and lesion size 
with corresponding statistical data. The “Out of’ column represents die totally number of melanoma in situ 
and stage I melanoma patients within each corresponding category. 
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of Stage I 
Melanoma 
Depth > mean 11 11 5 27 
0.3647 
Depth < mean 17 27 11 55 
Total 28 38 16 82 
Patient Sex Female 27 37 32 96 
0.9188 
Male 29 46 37 112 
Total 56 83 69 208 
Age Age > mean 24 50 43 117 
0.0271 
Age < mean 32 33 26 91 
total 56 83 69 208 
Size Size > mean 24 36 26 86 
0.9442 
Size < mean 32 47 43 122 
total 56 83 69 208 
Table 10: Trends during three 5 year periods: Data used to evaluate trends in patient mid 
lesion characteristics over 15 year time period with corresponding statistical data from the Chi-squared test. 
Evaluation of patient sex, age. and lesion size included melanoma in situ ;uul stage I melanoma in 
aggregate in an attempt to increase statistical significance. Mean depth of stage 1 melanoma was 0.42 
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